123 related articles for article (PubMed ID: 16232196)
1. Clinical significance of serum NM23-H1 protein in neuroblastoma.
Okabe-Kado J; Kasukabe T; Honma Y; Hanada R; Nakagawara A; Kaneko Y
Cancer Sci; 2005 Oct; 96(10):653-60. PubMed ID: 16232196
[TBL] [Abstract][Full Text] [Related]
2. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification.
Hailat N; Keim DR; Melhem RF; Zhu XX; Eckerskorn C; Brodeur GM; Reynolds CP; Seeger RC; Lottspeich F; Strahler JR
J Clin Invest; 1991 Jul; 88(1):341-5. PubMed ID: 2056128
[TBL] [Abstract][Full Text] [Related]
3. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2.
Godfried MB; Veenstra M; v Sluis P; Boon K; v Asperen R; Hermus MC; v Schaik BD; Voûte TP; Schwab M; Versteeg R; Caron HN
Oncogene; 2002 Mar; 21(13):2097-101. PubMed ID: 11960382
[TBL] [Abstract][Full Text] [Related]
4. Serum nm23-H1 protein as a prognostic factor in hematological malignancies.
Okabe-Kado J
Leuk Lymphoma; 2002 Apr; 43(4):859-67. PubMed ID: 12153176
[TBL] [Abstract][Full Text] [Related]
5. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas.
Leone A; Seeger RC; Hong CM; Hu YY; Arboleda MJ; Brodeur GM; Stram D; Slamon DJ; Steeg PS
Oncogene; 1993 Apr; 8(4):855-65. PubMed ID: 8384356
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes.
Valentijn LJ; Koppen A; van Asperen R; Root HA; Haneveld F; Versteeg R
Cancer Res; 2005 Apr; 65(8):3136-45. PubMed ID: 15833843
[TBL] [Abstract][Full Text] [Related]
7. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
8. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
Niitsu N; Okabe-Kado J; Kasukabe T; Yamamoto-Yamaguchi Y; Umeda M; Honma Y
Blood; 1999 Nov; 94(10):3541-50. PubMed ID: 10552965
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma.
Niitsu N; Honma Y; Iijima K; Takagi T; Higashihara M; Sawada U; Okabe-Kado J
Leukemia; 2003 Jan; 17(1):196-202. PubMed ID: 12529678
[TBL] [Abstract][Full Text] [Related]
11. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia.
Niitsu N; Okabe-Kado J; Nakayama M; Wakimoto N; Sakashita A; Maseki N; Motoyoshi K; Umeda M; Honma Y
Blood; 2000 Aug; 96(3):1080-6. PubMed ID: 10910925
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome.
Ito Y; Okabe-Kado J; Honma Y; Iwase O; Shimamoto T; Ohyashiki JH; Ohyashiki K
Leukemia; 2002 Feb; 16(2):165-9. PubMed ID: 11840281
[TBL] [Abstract][Full Text] [Related]
14. Physiological and pathological relevance of extracellular NM23/NDP kinases.
Okabe-Kado J; Kasukabe T
J Bioenerg Biomembr; 2003 Feb; 35(1):89-93. PubMed ID: 12848346
[TBL] [Abstract][Full Text] [Related]
15. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon T; Spitz R; Faldum A; Hero B; Berthold F
J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
[TBL] [Abstract][Full Text] [Related]
16. Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene encodes a novel protein, NM23-LV.
Valentijn LJ; Koster J; Versteeg R
Genomics; 2006 Apr; 87(4):483-9. PubMed ID: 16442775
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma specific effects of DR-nm23 and its mutant forms on differentiation and apoptosis.
Negroni A; Venturelli D; Tanno B; Amendola R; Ransac S; Cesi V; Calabretta B; Raschellà G
Cell Death Differ; 2000 Sep; 7(9):843-50. PubMed ID: 11042679
[TBL] [Abstract][Full Text] [Related]
18. A nucleoside diphosphate kinase A (nm23-H1) serine 120-->glycine substitution in advanced stage neuroblastoma affects enzyme stability and alters protein-protein interaction.
Chang CL; Strahler JR; Thoraval DH; Qian MG; Hinderer R; Hanash SM
Oncogene; 1996 Feb; 12(3):659-67. PubMed ID: 8637723
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma.
Niitsu N; Nakamine H; Okamoto M; Akamatsu H; Higashihara M; Honma Y; Okabe-Kado J; Hirano M
Clin Cancer Res; 2004 Apr; 10(7):2482-90. PubMed ID: 15073128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
